Glaukos Corp.

Glaukos Corp.

Glaukos Corp.

Overview
Date Founded

1998

Headquarters

26051 Merit Circle,Suite 103,Laguna Hills, CA 92653

Type of Company

Public

Employees (Worldwide)

600

Industries

Medical Products & Equipment
Medical Support Services
Hospitals & Patient Services

Company Description

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Contact Data
Trying to get in touch with decision makers at Glaukos Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer & Senior Vice President-Corporate Development

Chief Operating Officer

Secretary, Senior Vice President & General Counsel

Chief Medical Officer

Senior Vice President, Human Resources

Senior Vice President, New Technologies

Senior Vice President, Regulatory Affairs

Senior Vice President, Corporate Strategy & Business Development

Vice President, Research & Development, Combination Pharmaceutical Products

Paths to Glaukos Corp.
Potential Connections via
Relationship Science
You
Glaukos Corp.
Owners & Shareholders
Details Hidden

BCM evaluates the economic and investment environment to identify the most attractive companies for investment and desired market exposure. Their approach is primarily one of fundamental analysis in evaluating securities. Among the individual company factors considered in evaluating securities are past and prospective earnings and dividends, cash flow, return on equity and invested capital, asset value, and debt/equity ratio. Industry factors are also considered as part of the fundamental analysis, including competitive position versus peer groups worldwide, product cycles, barriers to entry, and global supply & demand conditions. Country factors include macroeconomic conditions, along with government, regulatory and cultural influences for international securities. Valuation analysis is utilized for securities to make a judgment whether the security is a superior investment value in both an absolute sense and relative to alternative rates of return in the financial markets on a risk adjusted basis. BCM utilizes financial newspapers, magazines, and periodicals to keep abreast of information of a general nature. The investment strategy employed by the firm generally involves establishing long term positions.

Details Hidden

Our firm was founded to help small investors build significant capital over time. Since we believe in owning as many promising stocks as possible, we generally buy on margin.* Borrowing to invest can force liquidations if the market collapses, so we try to balance this exposure by selling short. This ability to seek investments both up and downstream is rarely available to smaller investors. We, however, view it as an effective tool that doubles our clients' dollars at work (it also doubles our commissions), while moderately reducing their exposure to abrupt swings in the market. Our approach is not for the short-term investor. Clients must be able and willing to accept risks. Accounts will experience sharp fluctuations month to month, year to year. It takes a strong stomach to invest with us. Clients entrust decision making for their accounts to us: we buy and sell without asking our clients to authorize in advance each transaction. We are paid commissions for our work

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Recent Transactions
Details Hidden

Glaukos Corp. purchases Avedro, Inc.

Details Hidden

Glaukos Corp. purchases DOSE Medical Corp.

Details Hidden

Glaukos Corp. purchases Dose Medical Corp. /iDose Product Line from DOSE Medical Corp.

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onGlaukos Corp. issued USD Common Stock

Underwriter

Advised onGlaukos Corp. issued USD Common Stock

Underwriter

Advised onGlaukos Corp. issued USD Common Stock

Legal Advisor

Advised onGlaukos Corp. purchases Avedro, Inc.

Legal Advisor

Advised onGlaukos Corp. purchases Avedro, Inc.

Advisors & Consultants
Advisor

Former Chief Financial Officer & Secretary at DOSE Medical Corp.

Advisor

Senior Vice President-Strategy at Medtronic Plc

Key Stats and Financials As of 2019
Market Capitalization
$1.73B
Total Enterprise Value
$2.14B
Earnings Per Share
$0.37
Revenue
$237M
Net Profit
$15.4M
Total Debt
$75M
Total Equity
$673M
EBITDAMargin
-6.49%
EBITDA
$-15.4M
Enterprise Value Sales
9.04x
Debt TEV
0.04x
TEVNet Income
138.89x
Three Year Compounded Annual Growth Rate Of Revenue
27.48%
Five Year Compounded Annual Growth Rate Of Revenue
39.05%
Non-Profit Donations & Grants
Investors
Details Hidden

InterWest Partners focuses on early-stage investments in life sciences and information technology companies. Within the life sciences sector, the firm invests in a range of early-stage opportunities including the funding of preclinical companies with great potential. They also consider investing in or starting new companies around clinical or commercial stage assets. Within the information technology sector, InterWest looks for early-stage companies with near-term ROI-based value propositions. They favor investments in development-stage companies. Investments average $10 million to $15 million over the life of a company. InterWest serves as the lead investor in the majority of their investments.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made across three strategies: public equity, private equity, and royalty opportunities. OrbiMed Advisors manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts. They invest across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's private equity strategy is broad and flexible, investing from start-ups through growth equity. OrbiMed is typically a lead investor, seeking to help build our portfolio companies. Their geographic focus includes North America, Asia, Europe and Israel. For Royal Opportunities strategy, OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, they can monetize royalty streams, providing valuable financing solutions to owners of intellectual property.

Details Hidden

Meritech Capital Partners seeks investment opportunities in technology companies across the globe. The firm target companies operating in the fields of enterprise, consumer, fintech and healthtech. The firm provides financing for growth stage capital requirements.

Suppliers
D. Western Therapeutics Institute, Inc. Pharmaceuticals | Nagoya, Japan

D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. Its products include ophthalmic solution and agents for anti-platelet and anti-glaucoma. Its research and development laboratory undertakes drug design, screening of compounds, and selection of prospect compounds at early stage of drug research and development process. The company was founded by Hiroyoshi Hidaka on February 26, 1999 and is headquartered in Nagoya, Japan.

Santen Pharmaceutical Co., Ltd. Industrial Machinery & Manufacturing | Osaka, Japan

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Glaukos Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Glaukos Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Glaukos Corp..